Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study

Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study F. Nuzzo, C. Gallo, S. Lastoria, M. Di Maio, M. C. Piccirillo, A. Gravina, G. Landi, E. Rossi, C. Pacilio, V. Labonia, F. Di Rella, A. Bartiromo, G. Buonfanti, G. De Feo, G. Esposito, R. D’Aniello, P. Maiolino, S. Signoriello, E. De Maio , V. Tinessa, G. Colantuoni, M. De Laurentiis, M. D’Aiuto, M. Di Bonito, G. Botti, P. Giordano, G. Daniele, A. Morabito, N. Normanno, A. de Matteis & F. Perrone* Medical Oncology, Department of Senology, National Cancer Institute, Napoli; Medical Statistics, Department of Medicine and Public Health, Second University, Napoli; Nuclear Medicine and Metabolic Therapy, Department of Imaging, National Cancer Institute, Napoli; Clinical Trials Unit, Department of Research, National Cancer Institute, Napoli; Division of Medical Oncology, Department of Oncohematology, S.Giuseppe Moscati Hospital, Avellino; Laboratory Medicine, Department of Pathology and Laboratory Diagnostics, National Cancer Institute, Napoli; Department of Pharmacy, National Cancer Institute, Napoli; Division of Medical Oncology, Department of Oncology, Rummo Hospital, Benevento; Division of Surgical Oncology, Department of Senology, National Cancer Institute, Napoli; Pathology, Department of Pathology and Laboratory Diagnostics, National Cancer Institute, Napoli; Cellular Biology and Biotherapy, Department of Research, National Cancer Institute, Napoli, Italy